BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 29479351)

  • 1. T-Cell Metabolism in Hematopoietic Cell Transplantation.
    Nguyen HD; Kuril S; Bastian D; Yu XZ
    Front Immunol; 2018; 9():176. PubMed ID: 29479351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytotoxic Pathways in Allogeneic Hematopoietic Cell Transplantation.
    Du W; Cao X
    Front Immunol; 2018; 9():2979. PubMed ID: 30631325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T Cell Subsets in Graft Versus Host Disease and Graft Versus Tumor.
    Jiang H; Fu D; Bidgoli A; Paczesny S
    Front Immunol; 2021; 12():761448. PubMed ID: 34675938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
    Talmadge JE
    Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Role of Co-stimulatory/Co-inhibitory Signals in Graft-vs.-Host Disease.
    Kumar S; Leigh ND; Cao X
    Front Immunol; 2018; 9():3003. PubMed ID: 30627129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic Targets for Improvement of Allogeneic Hematopoietic Stem Cell Transplantation and Graft-vs.-Host Disease.
    Tijaro-Ovalle NM; Karantanos T; Wang HT; Boussiotis VA
    Front Immunol; 2019; 10():295. PubMed ID: 30891031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strategies for the identification of T cell-recognized tumor antigens in hematological malignancies for improved graft-versus-tumor responses after allogeneic blood and marrow transplantation.
    Zilberberg J; Feinman R; Korngold R
    Biol Blood Marrow Transplant; 2015 Jun; 21(6):1000-7. PubMed ID: 25459643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Immune tolerance induced by cytokines in allogeneic hematopoietic stem cell transplantation].
    Chang YJ; Huang XJ
    Beijing Da Xue Xue Bao Yi Xue Ban; 2009 Apr; 41(2):208-11. PubMed ID: 19377632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sphingolipid metabolism in T cell responses after allogeneic hematopoietic cell transplantation.
    Tian L; Ogretmen B; Chung BY; Yu XZ
    Front Immunol; 2022; 13():904823. PubMed ID: 36052066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Host-Derived CD70 Suppresses Murine Graft-versus-Host Disease by Limiting Donor T Cell Expansion and Effector Function.
    Leigh ND; O'Neill RE; Du W; Chen C; Qiu J; Ashwell JD; McCarthy PL; Chen GL; Cao X
    J Immunol; 2017 Jul; 199(1):336-347. PubMed ID: 28550198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The complex and central role of interferon-γ in graft-versus-host disease and graft-versus-tumor activity.
    Wang H; Yang YG
    Immunol Rev; 2014 Mar; 258(1):30-44. PubMed ID: 24517424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Graft versus host disease and cytokines].
    Itoh T
    Nihon Rinsho; 2003 Sep; 61(9):1504-11. PubMed ID: 14515716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic reprogramming of alloantigen-activated T cells after hematopoietic cell transplantation.
    Nguyen HD; Chatterjee S; Haarberg KM; Wu Y; Bastian D; Heinrichs J; Fu J; Daenthanasanmak A; Schutt S; Shrestha S; Liu C; Wang H; Chi H; Mehrotra S; Yu XZ
    J Clin Invest; 2016 Apr; 126(4):1337-52. PubMed ID: 26950421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TAK1 inhibition ameliorates survival from graft-versus-host disease in an allogeneic murine marrow transplantation model.
    Kobayashi A; Kobayashi S; Miyai K; Osawa Y; Horiuchi T; Kato S; Maekawa T; Yamamura T; Watanabe J; Sato K; Tsuda H; Kimura F
    Int J Hematol; 2018 Feb; 107(2):222-229. PubMed ID: 29027124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Related HLA-mismatched/haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion: observations of a single Chinese center.
    Huang X; Liu D
    Clin Transpl; 2011; ():237-45. PubMed ID: 22755417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Harnessing dendritic cells to improve allogeneic hematopoietic cell transplantation outcome.
    Hashimoto D; Merad M
    Semin Immunol; 2011 Feb; 23(1):50-7. PubMed ID: 21316261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autologous graft-versus-host disease: harnessing anti-tumor immunity through impaired self-tolerance.
    Kline J; Subbiah S; Lazarus HM; van Besien K
    Bone Marrow Transplant; 2008 Mar; 41(6):505-13. PubMed ID: 18026144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Role of Immune Checkpoint Molecules for Relapse After Allogeneic Hematopoietic Cell Transplantation.
    Köhler N; Ruess DA; Kesselring R; Zeiser R
    Front Immunol; 2021; 12():634435. PubMed ID: 33746972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of GvHD by suicide-gene transduced donor T lymphocytes: clinical applications in mismatched transplantation.
    Ciceri F; Bonini C; Gallo-Stampino C; Bordignon C
    Cytotherapy; 2005; 7(2):144-9. PubMed ID: 16040393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.